-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The FDA advisory panel recently voted 19-0 to recommend the COVID-19 vaccine Ad26.
COV2.
S to all recipients 18 years and older to be boosted at least two months after receiving the single-dose initial injection
.
Several committee members suggested that it should be treated as a two-dose vaccine, just like Pfizer/BioNTech’s Comirnaty and Moderna’s mRNA-1273
FDA COVID-19
Expert panel member Archana Chatterjee said: "A single dose of Ad26.
COV2.
S does not seem to provide sufficient protection like the mRNA vaccine, so it is indeed necessary to use a second dose to make it comparable to other vaccines in terms of effectiveness
.
"
Johnson & Johnson has proposed that its vaccines should also be boosted after an interval of at least six months, but it is also recommended to be vaccinated within two months at the earliest
.
In a briefing document issued before Friday's meeting, FDA scientists suggested that boosters should be given about two months later "may be beneficial," but questioned the company's data about a six-month interval between doses
Johnson & Johnson, head of vaccine development Johan Van Hoof told the committee, six months after the first vaccination strengthen immunity , resulting in 12-fold increase in the antibody, and the effectiveness of its variants (including Delta) is also increased in proportion
.
The company’s research results are based on 17 volunteers between the ages of 18 and 55.
Immunity when the results of the company's research based on 17 volunteers aged between 18 and 55 years, and one pair of larger study of 51 subjects found that two months after the first dose given booster, Its antibody has increased by nearly 5 times
At the same time, Johnson & Johnson executives Macaya Douoguih said there was no data show that people receiving the second dose Ad26.
COV2.
S troubles rare but serious risk of blood clotting disorders will increase
.
She cited data from the United Kingdom on AstraZeneca's second dose of the coronavirus vaccine Vaxzevria, which uses a platform similar to Johnson & Johnson's vaccine
The FDA may make a final decision on Johnson & Johnson's vaccine within a few days, and then it is expected that the CDC Vaccine Advisory Committee will meet to further discuss recommendations on who should receive the booster and when
Original source:
Original source:https://®ion_id=6
https://®ion_id=6 https://®ion_id=6 leave a message here
